March 25 - Complementary Use of Circulating Tumor Cell Sequencing and Tumor Sequencing

Availability

Registration ends on March 25, 2025

Expires on Apr 25, 2025

Online Meeting

Mar 25, 2025 11:00 AM - 12:00 PM ET

Cost

$0.00

Credit Offered

1 CME (AMA) Credit

1 CME (Other) Credit

Complementary Use of Circulating Tumor Cell Sequencing and Tumor Sequencing

Tuesday, March 25th, 2025
11:00am-12:00pm ET
www.acmgeducation.net

Course Description
Dr. Kanwar will discuss a case where extensive molecular profiling was used to inform patient management in a solid tumor through both circulating tumor DNA (ctDNA) and solid tumor sequencing. This case will highlight some advantages to performing each of these testing modalities and the overall impact on patient care.

Target Audience
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Agenda
Presentations followed by live Q&A.

Learning Objectives
At the conclusion of this session, participants should be able to:

1. List the differences between sequencing ctDNA and solid tumor DNA.
2. Explain why complementary ctDNA and solid tumor sequencing was helpful in this case.
3. Describe a situation where ctDNA sequencing is preferred to solid tumor sequencing.

Moderator:
Beth Pitel, MS

Clinical Variant Scientist, Mayo Clinic
Assistant Professor, Department of Laboratory Medicine and Pathology, Mayo Clinic

Nisha Kanwar, PhD
Laboratory Genetics and Genomics Fellow, Mayo Clinic
Department of Laboratory Medicine and Pathology

Planning Committee:
Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Manuela Benary, PhD
Jason Saliba, PhD
Jane Radford, MHA, CHCP
Claudia Barnett

CME AMA PRA Category 1 CreditTM, & CME Other

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Medical Genetics and Genomics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming your Educational Credits

Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days from the date of the activity. Educational credit requests after this date will not be accepted.

Learner Data Consent

ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.

Technical Support:

You can reach us by email at education@acmg.net or call 301-718-9603.

Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

All of the relevant financial relationships listed for these individuals have been mitigated.

NAME	ROLE			RELATIONSHIP/ COMPANY
	Planning Member	Presenter Panelist Moderator	Peer Reviewer
Nisha Kanwar PhD		●		Nothing to Disclose.
Beth Pitel, MS, CG(ASCP)	●	●		Advisory Board: Qiagen, LLC
Claudia Barnett	●			Nothing to Disclose.
Gordana Raca, MD, PhD, FACMG	●		●	Nothing to Disclose.
Jane Radford, MHA, CHCP	●			Nothing to Disclose.
Jason Saliba, PhD	●			Nothing to Disclose.
Manuela Benary, PhD	●			Speaker: Novartis